Supernus Pharmaceuticals SUPN Business Segments — Cost of revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's business segments — cost of revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's business segments — cost of revenues?
- Supernus Pharmaceuticals (SUPN) reported business segments — cost of revenues of $23.39M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — cost of revenues changed year-over-year?
- Supernus Pharmaceuticals's business segments — cost of revenues increased by 48.4% year-over-year, from $15.76M to $23.39M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — cost of revenues?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — cost of revenues has grown at a -5.1% compound annual growth rate (CAGR), from $87.22M to $74.56M.
- What does business segments — cost of revenues mean?
- Includes the direct costs associated with producing and delivering the pharmaceutical products sold by the segment. Monitoring this helps evaluate the efficiency of the manufacturing process and the impact of supply chain costs on gross margins.